Evidence map›Paper›PMID 26784641›Full record

ArticleHuman gene therapy2016

Gene Therapy: The View from NCATS.

Philip J Brooks, N Nora Yang, Christopher P Austin

Abstract read
In one paragraph

Article in Human gene therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Rarer dementias, limited options, and unaddressed needs.International psychogeriatrics · 2024
    Article
  2. Clustering rare diseases within an ontology-enriched knowledge graph.Journal of the American Medical Informatics Association : JAMIA · 2023
    Article
  3. Article
  4. Clustering rare diseases within an ontology-enriched knowledge graph.bioRxiv : the preprint server for biology · 2023
    Article
  5. Article
  6. Ethical challenges for a new generation of early-phase pediatric gene therapy trials.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Review
  7. Role of the HSP70 Co-Chaperone SIL1 in Health and Disease.International journal of molecular sciences · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Drug discovery and development for rare genetic disorders.American journal of medical genetics. Part A · 2017
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Philip J Brooks1 Division of Clinical Innovation and Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health , Bethesda, Maryland.
N Nora Yang2 Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health , Bethesda, Maryland.
Christopher P Austin3 Office of the Director, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health , Bethesda, Maryland.

Funding

Gene Therapy Platform for Rare DiseasesZIATR000281 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI OTTINGER, ELIZABETH · 2017 to 2025
$34.7M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genetic TherapyHumansNational Institutes of Health (U.S.)Translational Research, BiomedicalUnited States

Identifiers

PMID26784641
PMCPMC4743673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.